Table 4.
Changes in generic and disease-specific quality of life and symptom severity during 6–24 months of follow-up*
| Additional catheter-directed thrombolysis (n=90) |
Standard treatment only (n=99) |
||||
|---|---|---|---|---|---|
| n | % (95% CI) | n | % (95% CI) | p Value† | |
| Generic QOL | |||||
| EQ-5D improved | 15 | 16.7 (10.0 to 24.4) | 24 | 24.5 (16.6 to 33.4) | 0.233 |
| EQ-5D worsened | 22 | 24.4 (16.4 to 34.1) | 16 | 16.3 (9.9 to 24.4) | |
| Disease-specific QOL | |||||
| VEINES-QOL improved | 17 | 19.5 (11.8 to 28.0) | 27 | 27.3 (19.2 to 36.7) | 0.462 |
| VEINES-QOL worsened | 19 | 21.8 (13.6–30.4) | 19 | 19.2 (12.3 to 27.8) | |
| VEINES-Sym improved | 14 | 15.9 (9.1 to 24.2) | 32 | 32.3 (23.7 to 42.0) | 0.029 |
| VEINES-Sym worsened | 20 | 22.7 (14.5 to 31.7) | 21 | 21.2 (14.0 to 30.1) | |
| PTS (n=92) | No PTS (n=97) | ||||
| Generic QOL | |||||
| EQ-5D improved | 15 | 16.5 (9.8 to 24.9) | 24 | 24.7 (16.9 to 34.0) | 0.041 |
| EQ-5D worsened | 25 | 27.5 (18.8 to 36.9) | 13 | 13.4 (7.7 to 21.3) | |
| Disease-specific QOL | |||||
| VEINES-QOL improved | 21 | 23.3 (15.1 to 32.2) | 23 | 24.0 (16.1 to 32.9) | 0.017 |
| VEINES-QOL worsened | 26 | 28.9 (19.8 to 38.1) | 12 | 12.5 (6.9 to 20.1) | |
| VEINES-Sym improved | 20 | 22.0 (14.2 to 31.0) | 26 | 27.1 (18.7 to 36.3) | 0.017 |
| VEINES-Sym worsened | 28 | 30.8 (21.7 to 40.4) | 12 | 13.5 (7.7 to 21.3) | |
*A meaningful change was defined as ≥4 points for VEINES-QOL/Sym scores and ≥0.08 for the EQ-5D index; improvement or worsening below this was registered as no change.
†χ2 test.
QOL, quality of life.